Login to your account

Username *
Password *
Remember Me
Opinion | Tocilizumab in COVID-19 therapy: who benefits, and how? – the researchers suggest that maybe IL-6 inhibitors should be given only to patients with high IL-6.

Opinion | Tocilizumab in COVID-19 therapy: who benefits, and how? – the researchers suggest that maybe IL-6 inhibitors should be given only to patients with high IL-6.

Tocilizumab in COVID-19 therapy: who benefits, and how? – The Lancet Related: A living WHO guideline on drugs for covid-19 – interleukin-6 receptor blockers are now recommended for patients with severe or critical covid-19. AND M-A: Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 – “The 4% absolute risk reduction […]

The post Opinion | Tocilizumab in COVID-19 therapy: who benefits, and how? – the researchers suggest that maybe IL-6 inhibitors should be given only to patients with high IL-6. appeared first on Links Medicus.

Lu 546 fois
Évaluer cet élément
(0 Votes)

About Author

Laissez un commentaire

Assurez-vous d'entrer toutes les informations requises, indiquées par un astérisque (*). Le code HTML n'est pas autorisé.